Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model).

The STAM™ model was originally developed as a NASH model, but with a 100% incidence of hepatocellular carcinoma (HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development.

 

The model has the following features compared with other HCC models.

 

STAM™;

- shows prompt (by 20 wks of age) and definite (nearly 100%) disease development to HCC

- is non-genetic, NASH-associated cancer model that has the advantage of naturally-occurring tumor microenvironment

- allows a flexible treatment design for HCC therapeutics (preventive regimen/therapeutic regimen)

 

Please find below the comparison table of STAM™ model and other HCC models.

 

Fig. Comparison of STAM™ model with other HCC models.

 

In addition to the above, elevated levels of AFP, Glypican-3, and Glutamine synthetase, which are human HCC markers, have been observed in the STAM™ model.

We also have a CT system for small animals, which offers a multifaceted and accurate evaluation of disease progression.

 

We believe that a pharmacological study using this model could help you progress with the research and development of your compound.

 

Please don’t hesitate to contact us if you would like further information on any of these models or our services.